Oppenheimer Maintains Outperform on Abeona Therapeutics, Raises Price Target to $20
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Andreas Argyrides maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and raises the price target from $19 to $20.
Oppenheimer analyst Andreas Argyrides maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and raises the price target from $19 to $20.